Manfidokimab vs stapokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-4R-alpha · full Atopic Dermatitis pipeline
Manfidokimab
Developed by Akeso
NCT06383468 · Phase 3 · status unknown
This Phase 3 trial randomly assigned adults with moderate-to-severe atopic dermatitis to manfidokimab (AK120) or placebo, both delivered by subcutaneous injection, under quadruple-blind conditions, with the proportion of patients achieving EASI-75 (75% improvement in eczema severity) at week 16 as the primary endpoint. No results have been posted, so this remains a well-designed, adequately sized, blinded, placebo-controlled trial whose findings are not yet known.
Next expected readout: July 2027 · NCT06767540 (registry estimate)
No aligned efficacy figure on record for this race.
stapokibart
Marketed by Keymed Biosciences and partners
NCT05265923 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled Phase 3 trial in 500 adults with moderate-to-severe atopic dermatitis, significantly more patients receiving stapokibart achieved at least a 75% reduction in eczema severity at 16 weeks than those on placebo (66.9% vs 25.8%).
Next expected readout: February 2027 · NCT07106372 (registry estimate)
Reported efficacy
Proportion of subjects achieving EASI-75 at week 18 (Up to week 18); Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline (up to week 18): EASI-75 at week 18: 73.9% (88/119) stapokibart vs 43% (26/60) placebo; difference 30.5 percentage points (95% CI 15.3-44.3; P<0.001) (met)
Result source: NCT06277765
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Manfidokimab | stapokibart |
|---|---|---|
| EASI-75 | —Trial running · NCT06767540 | —Not posted · NCT05265923 |
| IGA 0/1 with 2-point improvement | —Trial running · NCT06767540 | —Not posted · NCT05265923 |
| EASI-90 | —Trial running · NCT06767540 | —Not posted · NCT05265923 |
| EASI, % change | —Trial running · NCT06767540 | —Not posted · NCT05265923 |
EASI-75
- Manfidokimab
- —Trial running · NCT06767540
- stapokibart
- —Not posted · NCT05265923
IGA 0/1 with 2-point improvement
- Manfidokimab
- —Trial running · NCT06767540
- stapokibart
- —Not posted · NCT05265923
EASI-90
- Manfidokimab
- —Trial running · NCT06767540
- stapokibart
- —Not posted · NCT05265923
EASI, % change
- Manfidokimab
- —Trial running · NCT06767540
- stapokibart
- —Not posted · NCT05265923
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Manfidokimab: no structured comparison results are available for Atopic Dermatitis.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Manfidokimab's landscape · stapokibart's landscape